Dr William Patrick Browne, MD | |
800 Stanton L Young Blvd, Oklahoma City, OK 73104-5018 | |
(405) 271-2316 | |
Not Available |
Full Name | Dr William Patrick Browne |
---|---|
Gender | Male |
Speciality | Student In An Organized Health Care Education/training Program |
Location | 800 Stanton L Young Blvd, Oklahoma City, Oklahoma |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1487259594 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208600000X | Surgery | 39611 (Oklahoma) | Secondary |
390200000X | Student In An Organized Health Care Education/training Program | (* (Not Available)) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr William Patrick Browne, MD 224 Ne 2nd St Apt 201, Oklahoma City, OK 73104-4067 Ph: () - | Dr William Patrick Browne, MD 800 Stanton L Young Blvd, Oklahoma City, OK 73104-5018 Ph: (405) 271-2316 |
News Archive
Amedica Corporation, a spinal and orthopaedic implant and instrument company focused on unique silicon nitride (SiN) ceramic technologies, announced today that it has been granted United States Patent No. 7,666,229 covering its novel ceramic-on-ceramic bearings for articulating joints used for total joint replacement and spinal disc applications.
A team of global partners has tasked itself with the daunting challenge of bringing mobility to disabled children of developing nations.
A recent study by a Saint Louis University researcher confirms findings that about half of the U.S. population has a version of a gene that causes them to metabolize food differently, putting them at greater risk of developing diabetes.
In a new report published in the Journal of Leukocyte Biology, scientists lay the groundwork for the development of novel tumor therapies that may help rid the body of cancer by inhibiting the recruitment of a specific suppressive immune cell type called "regulatory T-cells." The approach described in the report shows that an immune molecule, called interleukin-27, promotes the recruitment of regulatory T-cells.
› Verified 3 days ago